We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Collaborative Study of Thalidomide and Radiation Therapy in Glioblastoma

Apr 1, 1999
Volume: 
13
Issue: 
4
  • Brain Tumors

The Celgene Corporation is collaborating with
the National Cancer Institute’s Radiation Treatment Oncology
Group (RTOG) on a study of the use of thalidomide (Thalomid) in
conjunction with conventional surgery and radiation for the initial
treatment of glioblastoma multiforme. The study will enroll
approximately 80 patients and is designed to assess the drug’s
safety and efficacy in prolonging survival. Fifteen sites around the
country will be involved in the study.

According to lead investigators, the protocol will include patients
who have not previously undergone radiation therapy or chemotherapy.
Following surgery, participants will be given thalidomide, at a dose
of 200 mg once daily, on the first day of their radiation treatment.
Thereafter, each patient’s dose will increase by 100 to 200 mg
daily every 1 to 2 weeks, to a maximum dose of 1,200 mg daily.
Therapy will continue at that dose as long as no tumor progression or
toxicity occurs. The study is expected to last approximately 2 years.

“The RTOG is very excited about testing Thalomid with radiation,
in conjunction with Celgene Corporation,” said Walter J. Curran,
MD, group chairman of the RTOG.

Glioblastoma multiforme is a type of brain tumor that multiplies
rapidly and most often affects the cerebrum. It is the most common,
most often fatal type of malignant brain tumor and tends to recur
even after intensive treatment with surgery, chemotherapy, and
radiotherapy. The condition is diagnosed in approximately 9,000
individuals annually who live an average of 6 to 12 months after diagnosis.

For more information on the collaborative study call the Celgene
Corporation at (732) 271-4102.

Related Articles

  • Targeting Survivin May Open New Avenues for Immunotherapy
  • Common Genetic Driver Linked to Aggressive Meningiomas
  • Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies—PART 2: Existing Experience and Considerations for Future Trials
  • Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies—PART 1: Principles of Combined Treatment
  • Primary Central Nervous System Lymphoma—PART 2: Modern Therapeutic Management and Future Directions

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.